<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159756</url>
  </required_header>
  <id_info>
    <org_study_id>SMA-10-01</org_study_id>
    <nct_id>NCT01159756</nct_id>
  </id_info>
  <brief_title>To Assess the Safety and Efficacy of Travacom in Patients With Uncontrolled Intraocular Pressure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-site, unmasked phase IV study. Travacom(R) is a combination topical&#xD;
      ocular agent, containing travoprost and timolol, which lower intraocular pressure (IOP) by&#xD;
      complementary mechanisms of action. The safety and efficacy of both travoprost and timolol&#xD;
      have been established as single and adjunctive therapy in well-controlled clinical studies in&#xD;
      thousands of patients diagnosed with open angle glaucoma (OAG) or ocular hypertension. The&#xD;
      objective of this study is to assess the safety and efficacy of changing to Travacom from&#xD;
      prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular&#xD;
      hypertension across India.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy: Change in IOP at the final visit from prior beta-blocker monotherapy (Timolol 0.5% only)</measure>
    <time_frame>Baseline to Visit 3 (Week 6-8)</time_frame>
    <description>To assess the efficacy of changing to Travacom from prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular hypertension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Adverse Events.</measure>
    <time_frame>Baseline to Visit 3 (Week 6-8)</time_frame>
    <description>To assess the safety of changing to Travacom from prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular hypertension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Secondary efficacy: Percentage of subjects at target IOP (&lt;/ 18 mmHg), regardless of prior therapy.</measure>
    <time_frame>Baseline to Visit 3 (Week 6-8)</time_frame>
    <description>To assess the efficacy of changing to Travacom from prior pharmacotherapy in uncontrolled patients with open-angled glaucoma or ocular hypertension.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">468</enrollment>
  <condition>Uncontrolled Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Travacom</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travacom ophthalmic solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travacom</intervention_name>
    <description>Travacom ophthalmic solution (1 drop per day)</description>
    <arm_group_label>Travacom</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have a clinical diagnosis of ocular hypertension, primary open-angle or pigment&#xD;
             dispersion glaucoma in both eyes.&#xD;
&#xD;
          -  Must be willing to discontinue the use of all other ocular hypotensive medications&#xD;
             prior to receiving the study medication for the entire course of the study.&#xD;
&#xD;
          -  Must be able to follow instructions and be willing and able to attend all study&#xD;
             visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known medical history of allergy, hypersensitivity or poor tolerance to any&#xD;
             component of Travacom that is deemed clinically significant in the opinion of the&#xD;
             Principle Investigator.&#xD;
&#xD;
          -  Any abnormality preventing reliable applanation tonometer in either eye. Corneal&#xD;
             dystrophies.&#xD;
&#xD;
          -  Any opacity or subject uncooperativeness that restricts adequate examination of the&#xD;
             ocular fundus or anterior chamber of either eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Disha Eye Hospitals</name>
      <address>
        <city>Kolkata</city>
        <zip>700120</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>April 7, 2012</last_update_submitted>
  <last_update_submitted_qc>April 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Travacom</keyword>
  <keyword>Glaucoma</keyword>
  <keyword>Travoprost</keyword>
  <keyword>Timolol</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

